Nephrocare Health Services Ltd
Pursuant to Reg 30 of SEBI Listing Regulations, we wish to hereby inform that NephroPlus Health Services Kazakhstan LLP, an overseas subsidiary of the Company has entered into a Share Purchase ....
M&A
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 01 Sep 2026, 11:45 PM IST · BSE ID: 9ea6cbb4-20ea-44d8-8260-017a135a966e
View Original BSE Filing (PDF)
💡
In Simple Terms
A subsidiary of Nephrocare Health Services is buying a 100% stake in a Kazakhstan-based dialysis center for KZT 561.66 million.
🤖 AI Summary
- NephroPlus Health Services Kazakhstan LLP, a subsidiary, will acquire 100% of Dialysis Center Almaty LLP.
- The acquisition consideration is KZT 561.66 million (approximately ₹116.35 million) via cash.
- Target entity, Dialysis Center Almaty LLP, recorded a last audited turnover of KZT 527.44 million (approx. ₹10.93 crore).
- The acquisition aligns with Nephrocare Health Services' strategy to expand its international dialysis services network.
- Completion is subject to conditions precedent and regulatory approvals in the Republic of Kazakhstan.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Acquisition Consideration
KZT 561.66 million (Approx. ₹116.35 million)
Target Entity Last Audited Turnover
KZT 527.44 million (approx. ₹10.93 crore)
Participatory Interest Acquired
100%
🏢 How This Affects the Company
The acquisition expands Nephrocare Health Services' dialysis services network in international markets and strengthens its presence in Kazakhstan, aligning with its core business strategy.
The acquisition involves a cash consideration of KZT 561.66 million (approx. ₹116.35 million), which will impact the company's cash reserves upon completion.
Upon completion, Dialysis Center Almaty LLP will become an overseas step-down subsidiary, integrating its dialysis services into Nephrocare's operating platform in Kazakhstan.
The completion of the acquisition is subject to fulfilment of conditions precedent and regulatory approvals in Kazakhstan, introducing execution risks until transaction closure.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this disclosure.
👤
Who Is Affected
Shareholders are affected by the company's expansion into Kazakhstan and the deployment of KZT 561.66 million (approx. ₹116.35 million) in cash for the acquisition.
🔍
Management Signal
Management is signaling a clear intent to pursue international expansion and strengthen its presence in the dialysis services sector.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Announcement of the final completion date for the acquisition.
Updates on regulatory approvals from Kazakhstan authorities.
Company's next quarterly results for financial impact.
MEDIUM RISK
Completion is subject to conditions precedent and regulatory approvals, which could delay or alter the transaction.
💡 Investor Takeaway
Nephrocare Health Services' subsidiary has signed an agreement to acquire 100% participatory interest in Dialysis Center Almaty LLP for KZT 561.66 million (approx. ₹116.35 million) in cash. The target entity's last audited turnover was KZT 527.44 million (approx. ₹10.93 crore).
⚖️ Strengths & Concerns
✅ Positives
- Acquisition of 100% participatory interest in Dialysis Center Almaty LLP strengthens international presence and business strategy.
- The target entity's last audited turnover was KZT 527.44 million (approx. ₹10.93 crore), adding to Nephrocare's revenue base.
⚠️ Concerns
- The acquisition requires a cash consideration of KZT 561.66 million (Approx. ₹116.35 million), impacting immediate cash flow.
- Completion is subject to governmental and regulatory approvals and conditions precedent, indicating a non-immediate closure.
📅 Company Track Record
Nephrocare Health Services, through its subsidiaries, has been active in expanding its international presence. In June 2026, its subsidiary acquired Philippines dialysis center assets across four separate filings, totaling approximately PhP 294,880,000.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is the acquisition value of Dialysis Center Almaty by Nephrocare Health Services?
Nephrocare Health Services' overseas step-down subsidiary, NephroPlus Health Services Kazakhstan LLP, entered an agreement to acquire 100% participatory interest in Dialysis Center Almaty LLP for KZT 561.66 million (Approx. ₹116.35 million).
What was the last audited turnover of Dialysis Center Almaty LLP?
The last audited turnover of Dialysis Center Almaty LLP was KZT 527.44 million (approx. ₹10.93 crore).
What percentage of Dialysis Center Almaty will Nephrocare Health Services' subsidiary acquire?
NephroPlus Health Services Kazakhstan LLP will acquire 100% participatory interest in the charter capital of Dialysis Center Almaty LLP.
What is the payment method for the acquisition of Dialysis Center Almaty?
The consideration for the acquisition of Dialysis Center Almaty LLP is cash consideration.
Questions based on this BSE filing only. For information purposes.